↓ Skip to main content

Accelerating stem cell trials for Alzheimer's disease

Overview of attention for article published in Lancet Neurology, December 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
12 X users
facebook
5 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
190 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Accelerating stem cell trials for Alzheimer's disease
Published in
Lancet Neurology, December 2015
DOI 10.1016/s1474-4422(15)00332-4
Pubmed ID
Authors

Joshua G Hunsberger, Mahendra Rao, Joanne Kurtzberg, Jeff W M Bulte, Anthony Atala, Frank M LaFerla, Henry T Greely, Akira Sawa, Sam Gandy, Lon S Schneider, P Murali Doraiswamy

Abstract

At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and offer only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease.

X Demographics

X Demographics

The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 190 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 <1%
China 1 <1%
Germany 1 <1%
Unknown 187 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 33 17%
Student > Ph. D. Student 31 16%
Student > Bachelor 22 12%
Researcher 22 12%
Professor 12 6%
Other 29 15%
Unknown 41 22%
Readers by discipline Count As %
Neuroscience 29 15%
Agricultural and Biological Sciences 28 15%
Medicine and Dentistry 25 13%
Biochemistry, Genetics and Molecular Biology 21 11%
Pharmacology, Toxicology and Pharmaceutical Science 9 5%
Other 34 18%
Unknown 44 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 May 2020.
All research outputs
#1,146,796
of 25,374,917 outputs
Outputs from Lancet Neurology
#736
of 4,011 outputs
Outputs of similar age
#18,550
of 380,106 outputs
Outputs of similar age from Lancet Neurology
#16
of 76 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,011 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 380,106 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.